Janssen’s Rybrevant combo improves PFS in pre-treated EGFR-mutated NSCLC
The CHRYSALIS-2 study cohort evaluated the safety and tolerability of the combination of Rybrevant with Lazertinib plus platinum-based…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Sep 23
The CHRYSALIS-2 study cohort evaluated the safety and tolerability of the combination of Rybrevant with Lazertinib plus platinum-based…
12 Sep 23
SB17, a proposed biosimilar to Stelara (Ustekinumab), is Samsung Bioepis’ fourth candidate in the immunology pipeline, after SB4…
12 Sep 23
The partnership aims to pioneer innovative and transformative therapies for cancer patients facing substantial unmet medical needs
12 Sep 23
This transaction provides the Genentech and Roche R&D units with these three components of Herophilus’ discovery platform
11 Sep 23
Alexion will obtain access to the US-based biotechnology company’s CONVERGE platform to identify novel disease targets, in exchange…
11 Sep 23
The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Sep 23
Under the deal, Nurix will receive an upfront payment of $60m along with the potential to get research,…
11 Sep 23
Venlo, the Netherlands, and Redwood City, California, September 11, 2023 – QIAGEN Digital Insights, the bioinformatics business of QIAGEN, today…
08 Sep 23
The US-based biotechnology company will receive an upfront payment from Otsuka and is eligible to receive additional development,…
08 Sep 23
Ervebo is a live recombinant viral vaccine that has a VSV backbone removed for the VSV envelope glycoprotein…